retatrutide vs tirzepatide

retatrutide (S-tier) vs tirzepatide (S-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

retatrutide · tier S

the most potent weight loss drug ever tested. 24.2% in phase 2, then 28.3% in TRIUMPH-1 phase 3, 30.3% at two years. not approved yet.

the triple agonist with the highest weight-loss number ever recorded in a phase 3 obesity trial. not FDA-approved yet.

28.3% TRIUMPH-1 phase 3 · half-life ~6 days · weight loss

tirzepatide · tier S

A dual GIP and GLP-1 receptor agonist with distinct Zepbound and Mounjaro labels.

The obesity record is strong, but every outcome must stay attached to its trial population and product label.

20.9% SURMOUNT-1 mean change at 15 mg · half-life ~5 days · weight loss

at a glance

• retatrutide: tier S · 28.3% TRIUMPH-1 phase 3
• tirzepatide: tier S · 20.9% SURMOUNT-1 mean change at 15 mg

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.